| Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference |
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th at 8:30 a.m. ET. An audio webcast of the presentation can be accessed on the Investors section. |
businesswire.com |
2025-05-15 20:05:00 |
Czytaj oryginał (ang.) |
| Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones |
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its first-quarter 2025 financial results and affirmed its key clinical development milestones. “We remain on track to achieve all of our clinical operations milestones and significant clinical data readouts,” said Carm. |
businesswire.com |
2025-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development |
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical. |
businesswire.com |
2025-04-28 20:05:00 |
Czytaj oryginał (ang.) |
| Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors |
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025. “We are excited to welcome Diego to our board,” commented Eef Schimmelpennink, Contineum's Chairperson. “He has. |
businesswire.com |
2025-03-17 18:05:00 |
Czytaj oryginał (ang.) |
| Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum |
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18th at 12:30 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Contineum's websit. |
businesswire.com |
2025-03-12 18:05:00 |
Czytaj oryginał (ang.) |
| Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones |
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its fourth-quarter 2024 financial results and affirmed its key clinical development milestones. “2025 is shaping up to be a pivotal year, as we have several important clinical data readouts and trial initiations on the. |
businesswire.com |
2025-03-06 18:05:00 |
Czytaj oryginał (ang.) |
| Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791 |
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today initiated patient dosing in its exploratory PIPE-791 Phase 1b, randomized, double-blind, placebo-controlled, crossover, chronic pain trial. PIPE-791 is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic. |
businesswire.com |
2025-03-04 18:05:00 |
Czytaj oryginał (ang.) |
| Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference |
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2025 Leerink Partners Global Healthcare Conference on Tuesday, March 11th at 3:00 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section o. |
businesswire.com |
2025-03-03 18:05:00 |
Czytaj oryginał (ang.) |
| Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) |
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that it has completed the targeted enrollment of 168 patients in its Phase 2 PIPE-307 VISTA trial. PIPE-307 is a potentially first-in-class M1 receptor antagonist in development for patients with relapsing-remitting m. |
businesswire.com |
2025-01-08 18:05:00 |
Czytaj oryginał (ang.) |
| Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 |
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced dosing of the first cohort of patients in the PIPE-791 Phase 1b positron emission tomography (PET) tr. |
businesswire.com |
2024-12-16 18:05:00 |
Czytaj oryginał (ang.) |
| Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference |
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to participate in a fireside chat at the 7th Annual Evercore HealthCONx. |
businesswire.com |
2024-11-25 10:05:00 |
Czytaj oryginał (ang.) |
| Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain |
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced authorization of its Investigational New Drug (IND) application from the U.S. Food and Drug Administr. |
businesswire.com |
2024-11-18 10:05:00 |
Czytaj oryginał (ang.) |
| Contineum Therapeutics to Attend Upcoming Investor Conferences |
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to attend the following investor conferences during November 2024. Stife. |
businesswire.com |
2024-11-13 18:05:00 |
Czytaj oryginał (ang.) |
| Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences |
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced participation in the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference, Septembe. |
businesswire.com |
2024-08-28 20:05:00 |
Czytaj oryginał (ang.) |
| Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors |
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an indepen. |
businesswire.com |
2024-06-24 20:05:00 |
Czytaj oryginał (ang.) |
| Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model |
Contineum Therapeutics, Inc. PIPE-791 is being developed for the treatment of neuroinflammatory disorders like idiopathic pulmonary fibrosis and Progressive Multiple Sclerosis. The global idiopathic pulmonary fibrosis market size is projected to reach $6.45 billion by 2031. The global multiple sclerosis drugs market size is projected to reach $38.94 billion by 2032. |
seekingalpha.com |
2024-06-13 18:03:52 |
Czytaj oryginał (ang.) |
| Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference |
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that Company management will participate in the 45th Annual Goldman Sachs Healthcare Conference, taking place June 10-13, 2024. |
businesswire.com |
2024-06-04 20:05:00 |
Czytaj oryginał (ang.) |
| Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary |
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of John Healy as General Counsel & Corporate Secretary. “We are excited that John has joined Contineum, as. |
businesswire.com |
2024-06-03 20:05:00 |
Czytaj oryginał (ang.) |
| Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights |
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of NI&I indications, today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress. “2024 has been a pivotal year of growth for Contineum, as we transi. |
businesswire.com |
2024-05-16 20:05:00 |
Czytaj oryginał (ang.) |
| U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings |
Three IPOs priced in the first week of April, led by a sizable biotech. Two sizable listings are currently scheduled for the week ahead, although smaller issuers may join the calendar throughout the week. |
seekingalpha.com |
2024-04-06 09:50:00 |
Czytaj oryginał (ang.) |
| CTNM Stock: 7 Things to Know as Contineum Therapeutics Starts Trading Today |
Contineum Therapeutics (NASDAQ:CTNM) stock is a hot topic among traders on Friday as they prepare for the clinical-stage biopharmaceutical company's shares to go public today. Let's go over everything traders need to know about Contineum Therapeutics ahead of its initial public offering ( IPO ) later today! |
investorplace.com |
2024-04-05 13:13:13 |
Czytaj oryginał (ang.) |
| Contineum Therapeutics Announces Pricing of Initial Public Offering |
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Contineum Therapeutics, Inc. (Contineum), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology indications with high unmet need, today announced the pricing of its initial public offering of 6,875,000 shares of its Class A common stock at a price to the public of $16.00 per share. All of the shares are being offered by Contineum. The gross proceeds to Contineum from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Contineum, are expected to be $110.0 million. The shares are expected to begin trading on The Nasdaq Global Select Market on April 5, 2024 under the symbol “CTNM.” The offering is expected to close on April 9, 2024, subject to the satisfaction of customary closing conditions. In addition, Contineum has granted the underwriters a 30-day option to purchase up to an additional 1,031,250 shares of its Class A common stock at the initial public offering price, less underwriting discounts and commissions. |
globenewswire.com |
2024-04-05 01:02:00 |
Czytaj oryginał (ang.) |